Record First Half Despite Middle East Disruption

Anpario (LSE:ANP), the AIM-quoted producer of natural animal feed additives, is drawing attention after reporting first-half figures that showed growth in both sales and profitability. The interim results, reported on 11 September 2026, pointed to record sales for the six months to the end of June, with the group's higher-value branded products doing much of the heavy lifting. Management also flagged that conflict in the Middle East has been disrupting trade and that these pressures are expected to persist for the remainder of 2026.

What the Company Does

Anpario develops and sells natural feed additives designed to support animal health, nutrition and biosecurity. Its products are sold internationally, with sales reported across regions including the Americas, Asia and IMEA, the latter taking in the Middle East and Africa. Five leading brands, namely Orego-Stim, pHorce, Optomega, Mastercube and Bio-Vet, accounted for close to 80% of group revenue in the period and grew sales by 17%.

Latest Developments

Group sales rose 7% to £24.3 million in the first half of 2026. Regionally, IMEA was the fastest-growing area, with sales up 56%. The Americas grew 7% and has become the group's largest region, helped by a 19% rise in US sales. Within the US, the Bio-Vet on-farm portfolio increased 28% and pHorce sales rose 29%. Asia was the weak spot, with sales down 9%, largely reflecting lower demand for mycotoxin binders; excluding those products, the region grew 7%.

Operationally, the company reported early adoption of AmpLIPhy, a natural emulsifier, its first Middle East sales of Bio-Vet's QuadriCal bolus, and initial commercial sales through its Turkish subsidiary. Bio-Vet is being rebranded as Anpario from October as the group moves to a single global brand. Chairman Matthew Robinson said the board was pleased with the outcome, while acknowledging that macroeconomic conditions had tempered growth in some markets.

Financial and Dividend Picture

Adjusted EBITDA increased 22% to £5 million, and profit before tax rose 11% to £3.8 million. Diluted adjusted earnings per share climbed 30% to 20.77 pence. The company completed a £3 million share repurchase programme in July. Cash and cash equivalents stood at £11 million at the end of June. The interim dividend was raised 6% to 3.8 pence per share, adding to the cash returned through the buyback.

Sector and Index Context

Anpario sits within the agricultural inputs and animal health niche, a segment shaped by livestock economics, regulatory pressure to reduce antibiotic use, and demand for natural alternatives. As a constituent of the FTSE AIM All Share Index, it is one of a relatively small number of profitable, cash-generative, dividend-paying companies on the junior market. That profile contrasts with the many exploration and early-stage businesses that make up much of the AIM universe.

Key Risks

The most immediate risk is geopolitical, with the Middle East conflict already disrupting business and expected to continue weighing on activity. Exposure to agricultural commodity cycles, currency movements, and customer destocking, as seen in the Asian mycotoxin binder market, can also affect results. The rebranding of Bio-Vet carries execution risk, and integration of acquired operations requires ongoing management attention.

What to Watch Next

Investors are likely to focus on whether the momentum in IMEA and the Americas can offset weakness in Asia and Middle East disruption through the second half. The progress of the single-brand strategy from October, further capital allocation decisions after the completed buyback, and any trading update ahead of full-year results will be key indicators of whether the first-half pace can be sustained.